TARDBP and amyotrophic lateral sclerosis: In order to expand the preclinical validation to other genetic subtypes of ALS we set out to establish a dose response for NRF2 activation in the CNS as a precursor to investigating efficacy in a second, TARDBP mutant ALS mouse model for which we have validated readouts [32].